Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laila Huric

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Blood Cancer Journal|April 12, 2024
CD56 expression predicts response to Daratumumab-based regimensAllen J Robinette, Laila Huric, Kameron Dona, et al.
Blood Cancer Journal|November 10, 2023
Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myelomaMichael Ozga, Qiuhong Zhao, Laila Huric, et al.
Leukemia|June 20, 2024
CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myelomaAya Ismael, Allen J Robinette, Laila Huric, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Blood Cancer Journal|April 12, 2024
CD56 expression predicts response to Daratumumab-based regimensAllen J Robinette, Laila Huric, Kameron Dona, et al.
Blood Cancer Journal|November 10, 2023
Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myelomaMichael Ozga, Qiuhong Zhao, Laila Huric, et al.
Leukemia|June 20, 2024
CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myelomaAya Ismael, Allen J Robinette, Laila Huric, et al.
Pageof 1